News

TGV-inhalonix’s New Therapy Effective Against Resistant Fungal Lung Infections in CF Patients

Researchers at TGV-inhalonix said their company’s drug, Mul-1867, has a powerful effect against clinical isolates of fungi in patients with cystic fibrosis (CF) and other severe lung infections. The study “In vitro activity of a novel compound, Mul-1867, against clinically significant fungi Candida spp. and Aspergillus spp.” appeared in the International Journal of Antimicrobial…

Preclinical Study Identifies Spyryx’s SPX-101 as Potential Treatment for Mucus Clearance in CF Patients

Mutated mice that inhaled SPX-101 lived longer, according to a new preclinical study that highlights the drug’s potential to clear mucus and hydrate airways in patients with cystic fibrosis (CF). The study, “SPX-101 is a Novel ENaC-targeted Therapeutic for Cystic Fibrosis that Restores Mucus Transport,” appeared in the American Journal of…

AeroVanc Inhaled Powder for Cystic Fibrosis Infections Receives US and Canadian Patents

Savara has received U.S. and Canadian patents for its AeroVanc powdered, inhaled formulation of the antibiotic vancomycin hydrochloride, which combats treatment-resistant lung infections in cystic fibrosis (CF) patients. AeroVanc addresses the growing challenge of the methicillin-resistant Staphylococcus aureus (MRSA) bacteria, Savara said in a press release. The patents from the United States Patent and Trademark…

15 Non-profits in 7 Countries Win Vertex Grants for Cystic Fibrosis Projects

Fifteen non-profit groups in seven countries will receive Cystic Fibrosis Circle of Care project grants totaling nearly $1 million this year, the program’s sponsor, Vertex Pharmaceuticals, announced. The grants, now in their third year, go to medical, academic, patient, and community organizations serving the cystic fibrosis (CF) community. Since the program started in…

Your CF Community


Visit the Cystic Fibrosis News Today forums to connect with others in the CF community.